



03-14-05

B/1642  
CFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	09/615,285	
	Filing Date	July 12, 2000	
	First Named Inventor	Daniel E.H. Afar	
	Art Unit	1642	
	Examiner Name	G. B. Nickol	
Total Number of Pages in This Submission	3	Attorney Docket Number	511582000820


ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form  <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment/Reply  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Reply to Missing Parts/Incomplete Application  <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s) _____  <input type="checkbox"/> Landscape Table on CD	<input checked="" type="checkbox"/> After Allowance Communication to TC  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Summary of Interview (2 pages) Return Receipt Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	MORRISON & FOERSTER LLP (Customer No. 25226)		
Signature			
Printed name	Robert K. Cerpa		
Date	March 10, 2005	Reg. No.	39,933

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 335376055 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 10, 2005

Signature: (Georgina Matos)



PATENT  
Docket No. 511582000820

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 335376055 US, in an envelope addressed to: M.S. Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, CA 22313-1450, on the date shown below.

Dated: March 10, 2005

Signature: Georgina Matos (Georgina Matos)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Daniel E. H. AFAR et al.

Serial No.: 09/615,285

Filing Date: July 12, 2000

For: NOVEL TUMOR ANTIGEN USEFUL  
IN DIAGNOSIS AND THERAPY OF  
PROSTATE AND COLON CANCER

Examiner: G. Nickol

Group Art Unit: 1642

Confirmation No.: 3235

SUMMARY OF INTERVIEW

Mail Stop Issue Fee  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 CFR § 1.133 and MPEP § 713.04, the interview between Examiner Gary Nickol, Ph.D. and the undersigned agent (Robert Cerpa) on February 16, 2005 is hereby made of record.

Examiner Nickol contacted the undersigned agent by telephone on February 16, 2005 and left a message. The undersigned agent returned Examiner Nickol's call and reached the Examiner. No other parties participated in the interview. No exhibits were shown, nor were any demonstrations conducted. Pending claims 11, 19, 55, and 62-68 were discussed, although only claim 68 was discussed in any detail. No cited references were discussed.

Examiner Nickol indicated that the claims were allowable over the cited references of record. However, the Examiner objected to the recitation in claim 68 of "neoplastic cells,"

inasmuch as the claims were describing a method specific to prostate cancer. The undersigned agent authorized an Examiner's amendment changing "neoplastic cells" to "prostate cancer cells." (The undersigned agent notes that this change is not a narrowing amendment, as the claims were already limited to neoplasms of the prostate.) The authorized amendment also changed the dependency of claim 68 from claim 55 to claim 66, and "20P1F12/TMPRSS2 gene products evaluated in the test biological sample" was changed to "20P1F12/TMPRSS2 protein." Agreement was reached that claim 68 would be allowable with this amendment.

### **CONCLUSION**

In the event that the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. 511582000820.

Respectfully submitted,

Dated: March 10, 2005

By: \_\_\_\_\_

Robert K. Cerpa  
Registration No. 39,933

Morrison & Foerster LLP  
755 Page Mill Road  
Palo Alto, CA 94304-1018  
Telephone 650-813-5715  
Facsimile 650-494-0792